B. Riley analyst downgrades Cassava Sciences over limited data disclosures

Nov. 16, 2022 12:36 PM ETSAVABy: Mary Christine Joy, SA News Editor161 Comments

Closeup profile side view of woman hand showing white arrow pointing down, downgrade.


B. Riley analyst Mayank Mamtani downgraded the biotechnology company Cassava Sciences (SAVA) over limited relevant data disclosures.

Mamtani lowered the company to Neutral from Buy, with the price target maintained at $44.

The stock was trading ~9% down after the ratings action.

Recommended For You

Comments (161)

To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.